Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, controlled cohort study. This study will look at the
effect of Ethinyl Estradiol 35mcg/Norethindrone 1mg and Ethinyl Estradiol 20
mcg/Norethindrone 1mg on postpartum depressive symptoms and sexual function scores when
compared to a control group using no hormonal contraception. Depressive symptoms and sexual
function will be measured using the Edinburgh Postnatal Depression Scale (EPDS), Arizona
Sexual Experiences Scale (ASEX), and Brief Index of Sexual Functioning for Women (BISF-W).
Participants will begin taking the medication at Week 3 postpartum, and these outcomes will
be measured at baseline (0-1 day postpartum), Week 3, and Week 6-7. The investigators
hypothesize that there will be an ethinyl estradiol dose related response in EPDS, ASEX, and
BISF-W scores at Week 6-7, which would indicate a decrease in depressive symptoms and
increase in sexual function in both of the oral contraceptive groups.